

27 January 2020

Nuformix plc
("Nuformix" or "the Group"),

Resignation of John Lidgley

Nuformix, the pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs announces the resignation of John Lidgley from the Nuformix Board of Directors with effect on 31 January 2020. John chaired Levrett plc from inception through to the successful reverse merger with Nuformix in October 2017 and then remained on the Board as NED. He has now decided it is time to move on to pursue new opportunities.

Dr Dave Tapolczay, Chairman, Nuformix plc, said: *"On behalf of the Board and the Company, I would like to sincerely thank John for his work and commitment to the Board and the Company during his tenure, a period of accomplishment as Nuformix has established itself post the reverse merger with Levrett plc. The Board would like to wish John well in his future endeavours. John's departure creates an opportunity to bring new specialist life sciences experience to the Board, at a time when Nuformix faces exciting opportunities to continue its trajectory of progress and we look forward to updating shareholders on developments with both the Company and the Board in the near future"*

Market Abuse Regulation (MAR) Disclosure. Certain information contained in this announcement would have been deemed inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 until the publication of this announcement via a Regulatory Information Service and accordingly, this inside information is now considered to be in the public domain.

Enquiries:

Nuformix plc
Dr Dan Gooding, Chief Executive Officer
Email: info@nuformix.com

+44 (0)1223 627222

Novum Securities Limited
Jon Belliss / Colin Rowbury

+44 (0)20 7399 9427

About Nuformix plc www.nuformix.com

Nuformix is a pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs. Nuformix's risk-mitigated development strategy has resulted in a pipeline of discoveries through which it has developed and patented novel

cocrystal forms of approved small molecules.

Nuformix has created an IP portfolio of granted patents covering cocrystal forms of five small molecule drugs. Nuformix is targeting high-value unmet needs with its lead programmes in oncology supportive care: NXP001 and fibrosis: NXP002.

Nuformix was established in Cambridge in 2009 and has invested in pharmaceutical cocrystal R&D, establishing world-class capability and know-how in cocrystal discovery and development, yielding multiple product opportunities.

Nuformix plc shares are traded on the London Stock Exchange's Official List under the ticker: NFX.L.